Multiple Sclerosis

Fingolimod was first approved for adult patients with the relapsing form of MS, and was granted Priority Review and Breakthrough Therapy designation in December.

Late Friday afternoon, Novartis announced that the U.S. FDA approved fingolimod (Gilenya) to treat relapsing multiple sclerosis (MS) in children and adolescents age 10 years and older.

Genentech's global head of Neuroscience clinical development detailed the company's commitment to treating the progressive form of multiple sclerosis.

The vice president of Development Sciences for Biogen shared developments to come of the international MS PATHS collaboration.

This week on MDNN: Prolonged use of acetaminophen has been linked to an increase in the relative risk of ADHD and ASD, the ANA annual meeting issued 30 new recommendations for disease-modifying therapy for multiple sclerosis and the American Academy of Family Physicians announced a new Well-Being Planner to manage stressors and address burnout.

Patients from 2 demographically-different studies switching from interferon therapy to Aubagio reported similar improvements.

Lead author Alexander D. Rae-Grant, MD, explains the measures taken to ensure the panel got their 16-year multiple sclerosis recommendations update right.

The American Academy of Neurology has issued 30 recommendations for clinicians regarding disease-modifying therapies for multiple sclerosis.

Among patients with MS who began ocrelizumab treatment in the open-label extension, MRI lesion activity was almost completely suppressed.

A new study finding that 50% of low income Latino patients with MS suffer from depression is coupled with recent reports on their exclusion from clinical research.

The investigatory therapy for secondary progressive MS returned even more promising post hoc analysis prior to its FDA consideration.

James Stankiewicz, MD, discussed the current state of care in MS, what's in the pipeline, the advances that have been made, and what still remains to be done.

Although the causes of MS remain unknown, a variety of factors have been linked to exacerbations and relapse—and several that have recently been associated with increased risk of onset are avoidable.

Relapsing multiple sclerosis drug is removed from the market following reports of 8 cases of brain inflammation.

The promising relapsing MS therapy had previously shown benefits in relpase rates and T2 lesion limitation.

The Sandoz therapy now has received an indication for use in either 40 mg/mL or 20 mg/mL doses, with the lower quantity having been granted approval in June 2015.

A new study finds an endogenous metabolite, taurine, can make certain MS therapies more effective at spurring oligodendrocyte precursor cells to mature.

With the approval of drugs for progressive multiple sclerosis, the challenge surrounding infections has worsened.

A new study finds that when a blood protein crosses the blood-brain barrier, it can inhibit the brain’s ability to effect remyelination.

A team of researchers has successfully created oligodendrocytes from human and rodent cells.

Attendees at MS Paris 2017 discussed the biggest unmet needs in treating multiple sclerosis.

The first randomized controlled trial of a treatment to restore myelin in the MS patient CNS succeeded with an over-the-counter drug.

Teriflunomide was an effective first-line therapy for RRMS and a suitable switch therapy in real-world data.

The TOPIC study results additionally showed a strong association between CGMV loss and CDMS conversion.